Non-conformances in Pharmaceutical Laboratories

Pharmaceutical quality control laboratories are the guardians of public health. Through meticulous testing of raw materials, in-process materials, and finished products, they ensure the safety and efficacy of medications. However, nonconformances can arise during analyses, posing a threat to product quality and potentially violating regulatory requirements. These nonconformances encompass a range of issues, including results that fall outside established specifications (out-of-specification, OOS), trends that deviate from expected patterns (out-of-trend), and unforeseen events within the laboratory setting (laboratory incidents). Effectively addressing these nonconformances is critical not only for maintaining data integrity and safeguarding product quality, but also for achieving and sustaining compliance with stringent regulatory oversight. This ensures public trust in the safety and effectiveness of pharmaceutical products.

In pharmaceutical laboratories different non-conformances which can occur includes Out of specifications, Out of Trends, Laboratory Incidents etc.

Out of Specification Results:

In the pharmaceutical industry, “OOS” typically stands for “Out of Specification.” When a pharmaceutical product or a component of it does not meet its predetermined specifications or quality standards, it is considered as OOS result. This can happen during manufacturing, testing, or storage processes. OOS occurrences trigger investigations to determine the root cause and corrective actions to ensure product quality and regulatory compliance.

Refer to below examples:  

1. During routine testing, a sample from a batch of injectable drugs shows the presence of microbial contamination exceeding acceptable limits.
2. A batch of tablets is tested for potency, and the results show that the active ingredient content is lower or higher than the specified range in the formulation.
3. Analysis of a drug product sample confirms the presence of impurities that exceed the maximum allowed limits as per regulatory standards.
4. Samples from a stability study fail to meet the predetermined criteria for any specified test over a specified period, indicating potential issues with the product’s shelf life or storage conditions.

In each of these cases, when a result falls outside the specified limits, it triggers an investigation to determine the cause. This investigation involves reviewing analytical process, manufacturing processes, testing procedures, environmental conditions, and other relevant factors to identify any deviations or issues that may have led to the OOS result.

Out of Trend Results:

In the pharmaceutical industry, “OOT” typically stands for “Out of Trend.” OOT refers to a situation where data points or measurements from a process, test, or study begin to exhibit a consistent deviation or trend away from historical or expected values, even if they remain within specified limits. OOTs are departure of the results from the historical trend of results.

Refer to below examples:

1. Over the course of stability testing for a drug product, the degradation rate begins to increase beyond the expected trend, indicating a potential issue with the product’s shelf life or storage conditions.
2. Finished product analysis results for assay, impurity test were found to be outlier and not within a regular trend data.

Laboratory Incidents:

A laboratory incident in the pharmaceutical industry refers to any unexpected or undesirable event that occurs within a laboratory setting during the course of experiments, testing, or research activities. These incidents can vary in severity and can encompass a wide range of scenarios, including accidents, errors, equipment failures, and safety breaches.

Refer to below examples:

1. Equipment failures, Instrument failure, or malfunctions in analytical instruments, such as chromatography systems or spectrophotometers, can disrupt the testing.
2. Errors in recording details during analysis results, procedure, including errors and mislabelling of samples.

Laboratory incidents encompass any unexpected event that poses a threat to personnel, the environment, or the integrity of research. Spills, fires, equipment malfunctions, and even near misses fall under this category. Regulatory bodies expect laboratories to have a comprehensive plan for managing these incidents. This plan should include procedures for immediate response, thorough investigation to identify root causes, and implementation of corrective actions to prevent future occurrences. Detailed reporting is also crucial, as it allows regulatory agencies to monitor safety practices and identify potential trends.

Laboratory incidents differ from Out-of-Specification (OOS) results. OOS results occur when a sample fails to meet pre-defined quality criteria during testing. While they can indicate potential issues with the sample or the testing process, they don’t necessarily involve safety hazards or unexpected events. Incident reports focus on corrective actions to prevent future accidents, whereas OOS investigations aim to resolve the specific issue that caused the failed test and ensure data integrity.

When laboratory incidents occur, it is important for organizations to promptly investigate the root causes, implement corrective actions to prevent recurrence, and, if necessary, report the incident to relevant regulatory authorities. Additionally, ensuring a culture of safety, training personnel in proper laboratory practices, and maintaining robust quality management systems are essential for minimizing the risk of laboratory incidents in the pharmaceutical industry.

Key Takeaways for me?

In summary, non-conformances in the pharmaceutical industry are crucial for ensuring regulatory compliance, protecting patient safety, maintaining product quality, managing risks, driving continuous improvement, and enhancing customer satisfaction. Quality Control laboratory is the final stake holder who analyses and confirms the required quality standards through meticulous testing program. Therefore, any non-conformances in the laboratory has to be adequately dealt to ensure there is no impact on product quality or patient safety. Effective non-conformance management is integral to addressing these multifaceted issues, helping companies uphold the highest standards of quality, safety, and compliance while demonstrating a commitment to customer trust and loyalty.

References:

1. Title 21-Food and Drugs, Chapter I–Food and Drug Administration
2. Part 211-Current Good Manufacturing Practice for Finished Pharmaceuticals
3. Investigations for non-conformities guideline published by Indian Pharmaceutical Alliance.
4. ISO 9001:2015 in Section 10.2
5. ISO 13485:2016 in Section 8.3
6. FDA 21 CFR Part 820 in Section 21 CFR 820.90